This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idera Pharmaceuticals Announces Efficacy Data For IMO-8400 In Preclinical Models Of Lupus And Psoriasis

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs). The data were presented at the American Association of Immunologists (AAI) meeting being held in Boston, Massachusetts May 4-8, 2012.

“We are encouraged by the preclinical results with IMO-8400 as a novel approach for the treatment of lupus and other autoimmune disorders,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. “The dose-dependent protection we see in the lupus-prone mouse model suggests that pharmacologic inhibition of TLR7, 8, and 9 with IMO-8400 may provide a therapeutic strategy to suppress many lupus disease-associated parameters, including autoimmune antibodies, multiple pro-inflammatory serum cytokines, and indicators of kidney damage.”

A characteristic of SLE is the production of antinuclear autoantibodies complexed with self-RNA or -DNA. These abnormal antibodies inappropriately activate TLR7, 8, and 9 and initiate immune responses that damage the body’s own tissues and organs, thereby releasing more self-RNA and DNA. The data presented at AAI demonstrate that inhibition of TLR7, 8 and 9 with IMO-8400 suppressed the cycle between autoimmune antibody production and tissue damage, leading to improved renal function in lupus-prone mice. No treatment-related side effects were observed in the mice from IMO-8400 treatment at the doses employed in the study.

Idera expects to submit an Investigational New Drug application for IMO-8400 to the FDA during the fourth quarter of 2012, and has selected lupus as the initial disease indication for clinical development.

The oral presentation entitled “IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice” was made on May 5 th. In addition a poster presentation entitled “IMO-8400, a novel TLR7, TLR8, and TLR9 antagonist, inhibits disease development in mouse models of psoriasis” was presented at AAI on May 6 th. In the poster presentation, data demonstrated that IMO-8400 suppressed lesion development and related immunological makers in mouse models of psoriasis.

In addition to the above presentations, a poster presentation entitled “Modification of immune activation in HIV-1 infected humanized mouse model using TLR7/9 antagonists” was given in the Vaccine and Immunotherapy session on Sunday, May 6 th at 2:30 pm by investigators from the Ragon Institute of MIT, Massachusetts General Hospital, and Harvard Medical School in collaboration with Idera Pharmaceuticals.

These presentations are accessible on the Idera Pharmaceuticals website.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs